;PMID: 12385721
;source_file_819.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..46] = [t:0..46]
;1)sentence:[e:52..145] = [t:52..145]
;2)section:[e:149..183] = [t:149..183]
;3)section:[e:187..308] = [t:187..308]
;4)sentence:[e:312..379] = [t:312..379]
;5)sentence:[e:380..634] = [t:380..634]
;6)sentence:[e:635..792] = [t:635..792]
;7)sentence:[e:793..991] = [t:793..991]
;8)sentence:[e:992..1082] = [t:992..1082]
;9)sentence:[e:1084..1232] = [t:1084..1232]
;10)sentence:[e:1233..1320] = [t:1233..1320]
;11)sentence:[e:1321..1497] = [t:1321..1497]
;12)sentence:[e:1498..1588] = [t:1498..1588]
;13)sentence:[e:1589..1692] = [t:1589..1692]
;14)sentence:[e:1694..1922] = [t:1694..1922]
;15)sentence:[e:1924..2125] = [t:1924..2125]
;16)section:[e:2126..2171] = [t:2126..2171]
;17)section:[e:2175..2220] = [t:2175..2220]

;section 0 Span:0..46
;Chem Biol Interact. 2002 Oct 20;141(3):229-41.
(SEC
  (FRAG (NNP:[0..4] Chem) (NNP:[5..9] Biol) (NNP:[10..18] Interact)
        (.:[18..19] .) ('':[20..24] 2002) (NNP:[25..28] Oct)
        (CD:[29..36] 20;141-LRB-) (CD:[36..37] 3) (-RRB-:[37..38] -RRB-)
        (CD:[38..42] :229) (IN:[42..43] -) (CD:[43..45] 41) (.:[45..46] .)))

;sentence 1 Span:52..145
;In vitro metabolism of carbaryl by human cytochrome P450 and its inhibition
;by  chlorpyrifos.
;[75..83]:substance:"carbaryl"
;[93..108]:cyp450:"cytochrome P450"
;[132..144]:substance:"chlorpyrifos"
(SENT
  (NP-HLN
    (NP
      (NP
        (ADJP (FW:[52..54] In) (FW:[55..60] vitro))
        (NN:[61..71] metabolism))
      (PP (IN:[72..74] of)
        (NP (NN:[75..83] carbaryl)))
      (PP (IN:[84..86] by)
        (NP (JJ:[87..92] human)
           (NN:[93..103] cytochrome) (NN:[104..108] P450))))
    (CC:[109..112] and)
    (NP
      (NP (PRP$:[113..116] its) (NN:[117..127] inhibition))
      (PP (IN:[128..130] by)
        (NP (NN:[132..144] chlorpyrifos))))
    (.:[144..145] .)))

;section 2 Span:149..183
;Tang J, Cao Y, Rose RL, Hodgson E.
(SEC
  (FRAG (NNP:[149..153] Tang) (NNP:[154..156] J,) (NNP:[157..160] Cao)
        (NNP:[161..162] Y) (,:[162..163] ,) (NNP:[164..168] Rose)
        (NNP:[169..171] RL) (,:[171..172] ,) (NNP:[173..180] Hodgson)
        (NNP:[181..183] E.)))

;section 3 Span:187..308
;Department of Environmental and Molecular Toxicology, North Carolina State 
;University, Box 7633, Raleigh, NC 27695, USA.
(SEC
  (FRAG (NN:[187..197] Department) (IN:[198..200] of)
        (NNP:[201..214] Environmental) (CC:[215..218] and)
        (NNP:[219..228] Molecular) (NNP:[229..239] Toxicology) (,:[239..240] ,)
        (NNP:[241..246] North) (NNP:[247..255] Carolina) (NNP:[256..261] State)
        (NNP:[263..273] University) (,:[273..274] ,) (NNP:[275..278] Box)
        (CD:[279..283] 7633) (,:[283..284] ,) (NNP:[285..292] Raleigh)
        (,:[292..293] ,) (NNP:[294..296] NC) (CD:[297..302] 27695)
        (,:[302..303] ,) (NNP:[304..307] USA) (.:[307..308] .)))

;sentence 4 Span:312..379
;Carbaryl is a widely used anticholinesterase carbamate insecticide.
;[312..320]:substance:"Carbaryl"
;[338..378]:substance:"anticholinesterase carbamate insecticide"
(SENT
  (S
    (NP-SBJ (NN:[312..320] Carbaryl))
    (VP (VBZ:[321..323] is)
      (NP-PRD (DT:[324..325] a)
        (ADJP (RB:[326..332] widely) (VBN:[333..337] used))
        
        (NML (NN:[338..356] anticholinesterase) (NN:[357..366] carbamate))
        (NN:[367..378] insecticide)))
    (.:[378..379] .)))

;sentence 5 Span:380..634
;Although  previous studies have demonstrated that carbaryl can be metabolized
;by  cytochrome P450 (CYP), the identification and characterization of CYP
;isoforms  involved in metabolism have not been described either in humans or
;in  experimental animals.
;[430..438]:substance:"carbaryl"
;[462..477]:cyp450:"cytochrome P450"
;[479..482]:cyp450:"CYP"
;[528..540]:cyp450:"CYP isoforms"
(SENT
  (S
    (SBAR-ADV (IN:[380..388] Although)
      (S
        (NP-SBJ (JJ:[390..398] previous) (NNS:[399..406] studies))
        (VP (VBP:[407..411] have)
          (VP (VBN:[412..424] demonstrated)
            (SBAR (IN:[425..429] that)
              (S
                (NP-SBJ-1 (NN:[430..438] carbaryl))
                (VP (MD:[439..442] can)
                  (VP (VB:[443..445] be)
                    (VP (VBN:[446..457] metabolized)
                      (NP-1 (-NONE-:[457..457] *))
                      (PP (IN:[458..460] by)
                        (NP-LGS
                          (NP (NN:[462..472] cytochrome) (NN:[473..477] P450))
                          (NP (-LRB-:[478..479] -LRB-) (NN:[479..482] CYP)
                              (-RRB-:[482..483] -RRB-)))))))))))))
    (,:[483..484] ,)
    (NP-SBJ-2
      (NP (DT:[485..488] the) (NN:[489..503] identification) (CC:[504..507] and)
          (NN:[508..524] characterization))
      (PP (IN:[525..527] of)
        (NP
          (NP (NN:[528..531] CYP) (NNS:[532..540] isoforms))
          (VP (VBN:[542..550] involved)
            (NP (-NONE-:[550..550] *))
            (PP-CLR (IN:[551..553] in)
              (NP (NN:[554..564] metabolism)))))))
    (VP (VBP:[565..569] have) (RB:[570..573] not)
      (VP (VBN:[574..578] been)
        (VP (VBN:[579..588] described)
          (NP-2 (-NONE-:[588..588] *))
          (PP-LOC (CC:[589..595] either)
            (PP (IN:[596..598] in)
              (NP (NNS:[599..605] humans)))
            (CC:[606..608] or)
            (PP (IN:[609..611] in)
              (NP (JJ:[613..625] experimental) (NNS:[626..633] animals)))))))
    (.:[633..634] .)))

;sentence 6 Span:635..792
;The in vitro metabolic activities of human liver  microsomes (HLM) and human
;cytochrome P450 (CYP) isoforms toward carbaryl were  investigated in this
;study.
;[712..742]:cyp450:"cytochrome P450 (CYP) isoforms"
;[750..758]:substance:"carbaryl"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[635..638] The)
        (ADJP (FW:[639..641] in) (FW:[642..647] vitro))
        (JJ:[648..657] metabolic) (NNS:[658..668] activities))
      (PP (IN:[669..671] of)
        (NP
          (NP
            (NP (JJ:[672..677] human) (NN:[678..683] liver)
                (NNS:[685..695] microsomes))
            (NP (-LRB-:[696..697] -LRB-) (NN:[697..700] HLM)
                (-RRB-:[700..701] -RRB-)))
          (CC:[702..705] and)
          (NP (JJ:[706..711] human)
            
            (NML
              (NML (NN:[712..722] cytochrome) (NN:[723..727] P450))
              (NML (-LRB-:[728..729] -LRB-) (NN:[729..732] CYP)
                   (-RRB-:[732..733] -RRB-)))
            (NNS:[734..742] isoforms))))
      (PP (IN:[743..749] toward)
        (NP (NN:[750..758] carbaryl))))
    (VP (VBD:[759..763] were)
      (VP (VBN:[765..777] investigated)
        (NP-1 (-NONE-:[777..777] *))
        (PP (IN:[778..780] in)
          (NP (DT:[781..785] this) (NN:[786..791] study)))))
    (.:[791..792] .)))

;sentence 7 Span:793..991
;The three major metabolites, i.e. 5-hydroxycarbaryl,  4-hydroxycarbaryl and
;carbaryl methylol, were identified after incubation of  carbaryl with HLM or
;individual CYP isoforms and analysis by HPLC.
;[809..820]:substance:"metabolites"
;[827..844]:substance:"5-hydroxycarbaryl"
;[847..864]:substance:"4-hydroxycarbaryl"
;[869..886]:substance:"carbaryl methylol"
;[925..933]:substance:"carbaryl"
;[957..969]:cyp450:"CYP isoforms"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[793..796] The) (CD:[797..802] three) (JJ:[803..808] major)
          (NNS:[809..820] metabolites))
      (,:[820..821] ,)
      (NP
        (ADVP (FW:[822..826] i.e.))
        (NP (NN:[827..844] 5-hydroxycarbaryl))
        (,:[844..845] ,)
        (NP (NN:[847..864] 4-hydroxycarbaryl))
        (CC:[865..868] and)
        (NP (NN:[869..877] carbaryl) (NN:[878..886] methylol))))
    (,:[886..887] ,)
    (VP (VBD:[888..892] were)
      (VP (VBN:[893..903] identified)
        (NP-1 (-NONE-:[903..903] *))
        (PP-TMP (IN:[904..909] after)
          (NP
            (NP
              (NP (NN:[910..920] incubation))
              (PP (IN:[921..923] of)
                (NP (NN:[925..933] carbaryl)))
              (PP (IN:[934..938] with)
                (NP
                  (NP (NN:[939..942] HLM))
                  (CC:[943..945] or)
                  (NP (JJ:[946..956] individual)
                     (NN:[957..960] CYP) (NNS:[961..969] isoforms)))))
            (CC:[970..973] and)
            (NP
              (NP (NN:[974..982] analysis))
              (PP (IN:[983..985] by)
                (NP (NN:[986..990] HPLC))))))))
    (.:[990..991] .)))

;sentence 8 Span:992..1082
;Most of the  16 human CYP isoforms studied showed some metabolic activity
;toward carbaryl.
;[1014..1026]:cyp450:"CYP isoforms"
;[1073..1081]:substance:"carbaryl"
(SENT
  (S
    (NP-SBJ
      (NP (JJS:[992..996] Most))
      (PP (IN:[997..999] of)
        (NP
          (NP (DT:[1000..1003] the) (CD:[1005..1007] 16) (JJ:[1008..1013] human)
             (NN:[1014..1017] CYP) (NNS:[1018..1026] isoforms))
          (VP (VBN:[1027..1034] studied)
            (NP (-NONE-:[1034..1034] *))))))
    (VP (VBD:[1035..1041] showed)
      (NP
        (NP (DT:[1042..1046] some) (JJ:[1047..1056] metabolic)
            (NN:[1057..1065] activity))
        (PP (IN:[1066..1072] toward)
          (NP (NN:[1073..1081] carbaryl)))))
    (.:[1081..1082] .)))

;sentence 9 Span:1084..1232
;CYP1A1 and 1A2 had the greatest ability to form 5-hydroxycarbaryl, while
;CYP3A4  and CYP1A1 were the most active in generation of 4-hydroxycarbaryl.
;[1084..1090]:cyp450:"CYP1A1"
;[1084..1087]...[1095..1098]:cyp450:"CYP"..."1A2"
;[1132..1149]:substance:"5-hydroxycarbaryl"
;[1157..1163]:cyp450:"CYP3A4"
;[1169..1175]:cyp450:"CYP1A1"
;[1214..1231]:substance:"4-hydroxycarbaryl"
(SENT
  (S
    (NP-SBJ
      (NP
        (NML-1 (NN:[1084..1087] CYP))
        (NN:[1087..1090] 1A1))
      (CC:[1091..1094] and)
      (NP
        (NML-1 (-NONE-:[1094..1094] *P*))
        (NN:[1095..1098] 1A2)))
    (VP (VBD:[1099..1102] had)
      (NP (DT:[1103..1106] the) (JJS:[1107..1115] greatest)
          (NN:[1116..1123] ability)
        (S
          (NP-SBJ (-NONE-:[1123..1123] *))
          (VP (TO:[1124..1126] to)
            (VP (VB:[1127..1131] form)
              (NP (NN:[1132..1149] 5-hydroxycarbaryl))))))
      (,:[1149..1150] ,)
      (SBAR-ADV (IN:[1151..1156] while)
        (S
          (NP-SBJ (NN:[1157..1163] CYP3A4) (CC:[1165..1168] and)
                  (NN:[1169..1175] CYP1A1))
          (VP (VBD:[1176..1180] were)
            (NP-PRD (DT:[1181..1184] the)
              (ADJP (RBS:[1185..1189] most) (JJ:[1190..1196] active)))
            (PP (IN:[1197..1199] in)
              (NP
                (NP (NN:[1200..1210] generation))
                (PP (IN:[1211..1213] of)
                  (NP (NN:[1214..1231] 4-hydroxycarbaryl)))))))))
    (.:[1231..1232] .)))

;sentence 10 Span:1233..1320
;The  production of carbaryl methylol was primarily the result of metabolism
;by  CYP2B6.
;[1252..1269]:substance:"carbaryl methylol"
;[1313..1319]:cyp450:"CYP2B6"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1233..1236] The) (NN:[1238..1248] production))
      (PP (IN:[1249..1251] of)
        (NP (NN:[1252..1260] carbaryl) (NN:[1261..1269] methylol))))
    (VP (VBD:[1270..1273] was)
      (ADVP (RB:[1274..1283] primarily))
      (NP-PRD
        (NP (DT:[1284..1287] the) (NN:[1288..1294] result))
        (PP (IN:[1295..1297] of)
          (NP
            (NP (NN:[1298..1308] metabolism))
            (PP (IN:[1309..1311] by)
              (NP (NN:[1313..1319] CYP2B6)))))))
    (.:[1319..1320] .)))

;sentence 11 Span:1321..1497
;Differential activities toward carbaryl were observed among five  selected
;individual HLM samples with the largest difference occurring in the 
;production of carbaryl methylol.
;[1352..1360]:substance:"carbaryl"
;[1479..1496]:substance:"carbaryl methylol"
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[1321..1333] Differential) (NNS:[1334..1344] activities))
      (PP (IN:[1345..1351] toward)
        (NP (NN:[1352..1360] carbaryl))))
    (VP (VBD:[1361..1365] were)
      (VP (VBN:[1366..1374] observed)
        (NP-1 (-NONE-:[1374..1374] *))
        (PP (IN:[1375..1380] among)
          (NP (CD:[1381..1385] five) (VBN:[1387..1395] selected)
              (JJ:[1396..1406] individual) (NN:[1407..1410] HLM)
              (NNS:[1411..1418] samples)))
        (PP (IN:[1419..1423] with)
          (S-NOM
            (NP-SBJ (DT:[1424..1427] the) (JJS:[1428..1435] largest)
                    (NN:[1436..1446] difference))
            (VP (VBG:[1447..1456] occurring)
              (PP (IN:[1457..1459] in)
                (NP
                  (NP (DT:[1460..1463] the) (NN:[1465..1475] production))
                  (PP (IN:[1476..1478] of)
                    (NP (NN:[1479..1487] carbaryl) (NN:[1488..1496] methylol))))))))))
    (.:[1496..1497] .)))

;sentence 12 Span:1498..1588
;Co-incubations of carbaryl and chlorpyrifos in  HLM greatly inhibited
;carbaryl metabolism.
;[1516..1524]:substance:"carbaryl"
;[1529..1541]:substance:"chlorpyrifos"
;[1568..1576]:substance:"carbaryl"
(SENT
  (S
    (NP-SBJ
      (NP (AFX:[1498..1500] Co) (HYPH:[1500..1501] -)
          (NNS:[1501..1512] incubations))
      (PP (IN:[1513..1515] of)
        (NP (NN:[1516..1524] carbaryl) (CC:[1525..1528] and)
            (NN:[1529..1541] chlorpyrifos)))
      (PP-LOC (IN:[1542..1544] in)
        (NP (NN:[1546..1549] HLM))))
    (ADVP (RB:[1550..1557] greatly))
    (VP (VBD:[1558..1567] inhibited)
      (NP (NN:[1568..1576] carbaryl) (NN:[1577..1587] metabolism)))
    (.:[1587..1588] .)))

;sentence 13 Span:1589..1692
;The ability of HLM to metabolize  carbaryl was also reduced by pre-incubation
;of HLM with chlorpyrifos.
;[1623..1631]:substance:"carbaryl"
;[1679..1691]:substance:"chlorpyrifos"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[1589..1592] The) (NN:[1593..1600] ability)
        (S-1 (-NONE-:[1600..1600] *ICH*)))
      (PP (IN:[1601..1603] of)
        (NP (NN:[1604..1607] HLM)))
      (S-1
        (NP-SBJ (-NONE-:[1607..1607] *))
        (VP (TO:[1608..1610] to)
          (VP (VB:[1611..1621] metabolize)
            (NP (NN:[1623..1631] carbaryl))))))
    (VP (VBD:[1632..1635] was)
      (ADVP (RB:[1636..1640] also))
      (VP (VBN:[1641..1648] reduced)
        (NP-2 (-NONE-:[1648..1648] *))
        (PP (IN:[1649..1651] by)
          (NP-LGS
            (NP (AFX:[1652..1655] pre) (HYPH:[1655..1656] -)
                (NN:[1656..1666] incubation))
            (PP (IN:[1667..1669] of)
              (NP (NN:[1670..1673] HLM)))
            (PP (IN:[1674..1678] with)
              (NP (NN:[1679..1691] chlorpyrifos)))))))
    (.:[1691..1692] .)))

;sentence 14 Span:1694..1922
;Chlorpyrifos inhibited the generation of carbaryl methylol, catalyzed 
;predominately by CYP2B6, more than other pathways, correlating with an
;earlier  observation that chlorpyrifos is metabolized to its oxon primarily
;by CYP2B6.
;[1694..1706]:substance:"Chlorpyrifos"
;[1735..1752]:substance:"carbaryl methylol"
;[1782..1788]:cyp450:"CYP2B6"
;[1862..1874]:substance:"chlorpyrifos"
;[1897..1901]:substance:"oxon"
;[1915..1921]:cyp450:"CYP2B6"
(SENT
  (S
    (NP-SBJ (NN:[1694..1706] Chlorpyrifos))
    (VP (VBD:[1707..1716] inhibited)
      (NP
        (NP (DT:[1717..1720] the) (NN:[1721..1731] generation))
        (PP (IN:[1732..1734] of)
          (NP
            (NP (NN:[1735..1743] carbaryl) (NN:[1744..1752] methylol))
            (,:[1752..1753] ,)
            (VP (VBN:[1754..1763] catalyzed)
              (NP (-NONE-:[1763..1763] *))
              (ADVP (RB:[1765..1778] predominately))
              (PP (IN:[1779..1781] by)
                (NP-LGS (NN:[1782..1788] CYP2B6)))))))
      (,:[1788..1789] ,)
      (ADVP
        (ADVP (RBR:[1790..1794] more))
        (PP (IN:[1795..1799] than)
          (NP (JJ:[1800..1805] other) (NNS:[1806..1814] pathways))))
      (,:[1814..1815] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[1815..1815] *))
        (VP (VBG:[1816..1827] correlating)
          (PP-CLR (IN:[1828..1832] with)
            (NP (DT:[1833..1835] an) (JJR:[1836..1843] earlier)
                (NN:[1845..1856] observation)
              (SBAR (IN:[1857..1861] that)
                (S
                  (NP-SBJ-1 (NN:[1862..1874] chlorpyrifos))
                  (VP (VBZ:[1875..1877] is)
                    (VP (VBN:[1878..1889] metabolized)
                      (NP-1 (-NONE-:[1889..1889] *))
                      (PP (TO:[1890..1892] to)
                        (NP (PRP$:[1893..1896] its) (NN:[1897..1901] oxon)))
                      (ADVP (RB:[1902..1911] primarily))
                      (PP (IN:[1912..1914] by)
                        (NP-LGS (NN:[1915..1921] CYP2B6))))))))))))
    (.:[1921..1922] .)))

;sentence 15 Span:1924..2125
;Therefore, carbaryl metabolism in humans and its interaction with other 
;chemicals is reflected by the concentration of CYP isoforms in HLM and their 
;activities in the metabolic pathways for carbaryl.
;[1935..1943]:substance:"carbaryl"
;[1997..2006]:substance:"chemicals"
;[2044..2056]:cyp450:"CYP isoforms"
;[2116..2124]:substance:"carbaryl"
(SENT
  (S
    (ADVP (RB:[1924..1933] Therefore))
    (,:[1933..1934] ,)
    (NP-SBJ-1
      (NP
        (NP (NN:[1935..1943] carbaryl) (NN:[1944..1954] metabolism))
        (PP-LOC (IN:[1955..1957] in)
          (NP (NNS:[1958..1964] humans))))
      (CC:[1965..1968] and)
      (NP
        (NP (PRP$:[1969..1972] its) (NN:[1973..1984] interaction))
        (PP (IN:[1985..1989] with)
          (NP (JJ:[1990..1995] other) (NNS:[1997..2006] chemicals)))))
    (VP (VBZ:[2007..2009] is)
      (VP (VBN:[2010..2019] reflected)
        (NP-1 (-NONE-:[2019..2019] *))
        (PP (IN:[2020..2022] by)
          (NP-LGS
            (NP
              (NP (DT:[2023..2026] the) (NN:[2027..2040] concentration))
              (PP (IN:[2041..2043] of)
                (NP (NN:[2044..2047] CYP) (NNS:[2048..2056] isoforms)))
              (PP-LOC (IN:[2057..2059] in)
                (NP (NN:[2060..2063] HLM))))
            (CC:[2064..2067] and)
            (NP
              (NP (PRP$:[2068..2073] their) (NNS:[2075..2085] activities))
              (PP (IN:[2086..2088] in)
                (NP
                  (NP (DT:[2089..2092] the) (JJ:[2093..2102] metabolic)
                      (NNS:[2103..2111] pathways))
                  (PP (IN:[2112..2115] for)
                    (NP (NN:[2116..2124] carbaryl))))))))))
    (.:[2124..2125] .)))

;section 16 Span:2126..2171
;(Supported by NCDA  Environmental Trust Fund)
(SEC
  (FRAG (-LRB-:[2126..2127] -LRB-) (VBN:[2127..2136] Supported)
        (IN:[2137..2139] by) (NN:[2140..2144] NCDA)
        (NNP:[2146..2159] Environmental) (NNP:[2160..2165] Trust)
        (NNP:[2166..2170] Fund) (-RRB-:[2170..2171] -RRB-)))

;section 17 Span:2175..2220
;PMID: 12385721 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2175..2179] PMID) (::[2179..2180] :) (CD:[2181..2189] 12385721)
        (IN:[2190..2191] -LSB-) (NNP:[2191..2197] PubMed) (HYPH:[2198..2199] -)
        (JJ:[2200..2207] indexed) (IN:[2208..2211] for)
        (NNP:[2212..2220] MEDLINE-RSB-)))
